focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 shakes off midday losses after US data

Tue, 24th Oct 2023 17:08

(Alliance News) - The FTSE 100 closed in the green on Tuesday following positive private sector data out of the US, despite figures closer to home showing a weaker UK private sector and rising unemployment.

London equities were in the red around midday, unlike European peers, as the banking sector weighed on the FTSE 100 following less-than-stellar results from Barclays.

The FTSE 100 index closed up 14.87 points, 0.2%, at 7,389.70. The FTSE 250 ended down 64.89 points, 0.4%, at 16,994.10, and the AIM All-Share closed down 1.96 points, 0.3%, at 678.45.

The Cboe UK 100 ended up 0.2% at 737.16, the Cboe UK 250 closed down 0.5% at 14,738.75, and the Cboe Small Companies ended down 0.2% at 12,692.94.

In European equities, the CAC 40 in Paris ended up 0.6%, while the DAX 40 in Frankfurt ended up 0.5%.

The US private sector saw moderate expansion in October, following largely stagnant output in September and August, according to the latest flash estimate from S&P Global.

The headline S&P Global US purchasing managers' index rose to 51.0 in October, from 50.2 in September. Rising above the 50.0 no-change mark, it signalled a modest up-tick in business activity in the month.

S&P Global said the upturn was supported by expansions in activity for manufacturers and service providers alike. It noted that demand conditions for manufacturers improved for the first time since April, while service providers witnessed a slower drop in new orders.

The flash US manufacturing PMI stood at 50.0 in October, up fractionally from 49.8 in September. The flash US services business activity index stood at 50.9, up from 50.1 last month.

Both flash estimates were better than expected by markets. The sectors had been expected to remain in contraction territory, according to FXStreet-cited consensus.

The dollar gained ground in the wake of the print.

The pound was quoted at USD1.2163 at the London equities close on Tuesday in London, lower compared to USD1.2226 on Monday. The euro stood at USD1.0588, lower against USD1.0639. Against the yen, the dollar was trading at JPY149.90, higher compared to JPY149.79.

Stocks in New York were higher at the London equities close, with the DJIA up 0.6%, the S&P 500 index up 0.6%, and the Nasdaq Composite up 0.7%.

Coca-Cola was up 2.6% in New York at the London close.

The Atlanta, Georgia-based soft drink maker said revenue in the three months to September 29 increased 8.0% on-year to USD11.95 billion from USD11.06 billion. Net income was 9.2% higher at USD3.08 billion from USD2.82 billion.

Coca-Cola now expects organic revenue growth between 10% and 11% in 2023, having previously predicted a rise between 8% and 9%. It now expects comparable currency neutral earnings per share growth of 13% to 14%, lifted from its previous growth range of 9% to 11%.

"Being one of the strongest brands in the world, Coca-Cola's got plenty of staying power, and there's a lot to be said for that in an uncertain environment," said Hargreaves Lansdown analyst Aarin Chiekrie.

Investors also reacted to signs of a cooling UK economy in the latest PMI data.

The S&P Global/CIPS flash UK flash composite PMI rose slightly to 48.6 points in October from 48.5 in September. However, sitting below the 50.0 no change mark, the latest reading suggests the private sector remains in decline.

Looking ahead, S&P said concerns about the outlook for business and consumer spending meant that output growth expectations for the year ahead were the lowest since December 2022.

"Observers will take some comfort from the fact that PMIs do not account for the whole economy, although last week's lacklustre retail sales figures (which are excluded from PMIs) are not especially encouraging," said Handelsbanken analyst Daniel Mahoney.

The unemployment rate for the period for June to August was estimated at 4.2%. This was a 0.2 percentage point increase compared with the period from March to May, the the Office for National Statistics said.

The ONS explained that the figures are an "alternative series of estimates", due to "increased uncertainty" around the Labour Force Survey estimates.

Last month, the ONS said unemployment stood at 4.3% in the three months ended July.

In the FTSE 100, Rio Tinto was the top performer, rising 3.5%, after Barclays raised its rating for the London-based mining company to 'overweight' from 'equal weight'.

AstraZeneca was the second-best performer, rising 3.4% and building on Monday's gains from its Enhertu treatment being approved by the European Commission to treat adult lung cancer patients.

On Tuesday, the Cambridge-based pharmaceutical firm said the US health watchdog has approved a review for its FluMist Quadrivalent self-administered flu vaccine.

The US Food & Drug Administration accepted the drugmaker's supplemental biologics licence application for the needle-free nasal spray. It expects a regulatory decision on the product during the first quarter of 2024. If approved then, FluMist is expected to be available in the US for the 2024/2025 flu season.

If the product is reviewed, it will be the first flu vaccine available to be self-administered, "adding an additional option to be vaccinated against influenza".

Barclays was the second-worst performing FTSE 100 stock, losing 6.5%.

For the quarter that ended September 30, the bank's total income rose 5.2% on-year to GBP6.26 billion from GBP5.95 billion a year prior. However, the figure fell short of the GBP6.29 billion company-compiled consensus.

Barclays reported pretax profit of GBP1.89 billion for the quarter, down 4.3% on-year from GBP1.97 billion. However, it beat the company-compiled market consensus of GBP1.77 billion.

Looking ahead, Barclays backed its annual return on tangible equity forecast of "greater than 10%".

However, it trimmed UK net interest margin guidance. It now expects this to land around "3.05% to 3.10% in 2023".

In a negative read-across, rival banks NatWest and Lloyds Banking were down 1.9% and 1.4%, respectively.

Bunzl lost 4.0% after the distribution firm said revenue in the third-quarter of the year declined by 4.8% at constant exchange rates.

Bunzl put the revenue fall to a "continued decline in Covid-19 related product sales" and a lesser benefit from inflation. It also said there was a "wider post-pandemic related normalisation trends which drove expected volume weakness".

In the FTSE 250, CAB Payments was by far the worst performer, with its shares plunging 72%.

The cross-border payments and foreign exchange firm now expects annual revenue to be "at least" 20% ahead of the GBP109.4 million achieved in 2022. This is about 17% below its previous guidance, however.

It expects the "majority of any revenue impact" will hit its bottom line but will be seeking opportunities to lessen the impact on its bottom line.

Softcat was the second-worst FTSE 250 performer, falling 12%. This was despite reporting "another record year", the IT infrastructure and services provider said.

It reported a pretax profit of GBP141.9 million for the year ended July 31, up 4.2% from GBP136.1 million the year prior. Revenue dropped 8.6% to GBP985.3 million from GBP1.08 billion.

The decline was primarily driven by its Hardware segment, which saw revenue drop 24% year-on-year to GBP610.6 million. Meanwhile, revenue for its Software and Services segments grew 26% and 43%, respectively.

Elsewhere in London, FD Technologies lost 33% after the County Down, Northern Ireland-based group said it swung to a pretax loss of GBP4.5 million in the six months that ended August 31 from a profit of GBP1.1 million a year earlier.

Revenue fell to GBP142.5 million from GBP147.4 million, while it said it expects financial 2024 revenue in the range of GBP285 million to GBP295 million, from GBP296.0 million a year earlier.

Brent oil was lower at USD86.37 a barrel at the London equities close on Tuesday from USD91.05 late Monday. Gold was lower at USD1,963.03 from USD1,977.60.

In Wednesday's UK corporate calendar, a slew of trading statements are released, including by Fresnillo, Ibstock, Lloyds Banking and Reckitt Benckiser.

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.